NCT04309591

Cytosorb Therapy in Cardiac Surgery

Cytosorb Therapy in Cardiac Surgery - a Retrospective Study of Hemoadsorption in Patients With Endocarditis

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 249 (actual)
• Sponsor: University Hospital, Basel, Switzerland · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Cardiopulmonary surgery is associated with inflammatory responses that can lead to systemic inflammatory responses (SIRS), organ dysfunction (MOD) and death especially in patients with endocarditis. Cytokine removal might therefore improve outcomes of patients undergoing cardiac surgery. CytoSorb is a device designed to remove cytokine (IL-6, IL-10, TNFalpha) from the blood to reduce immune reactions. This trial investigates the use of CytoSorb during cardiac surgery in patients with endocarditis at the University Hospital Basel.

Conditions

• Cardiopulmonary Surgery
• Endocarditis
• Peri-operative Cytokines Levels

Interventions

Type	Name	Description
DEVICE	CytoSorb haemoadsorption (HA) device	CytoSorb® cartridges contain biocompatible sorbent polystyrene divinylbenzene beads coated with polyvinylpyrrolidone, capable of removing inflammatory molecules (eg Interleukin). The cartridge is inserted in a cardio-pulmonary bypass circuit to remove inflammatory molecules during cardiac surgery .

Timeline

• Start date: 2019-10-18
• Primary completion: 2019-12-04
• Completion: 2019-12-04
• First posted: 2020-03-16
• Last updated: 2020-03-16

Locations

1 site across 1 country: Switzerland